Ivermectin in COVID-19: What do we know?

Pandey, Sanjay; Pathak, Subodh Kumar; Pandey, Apurva; Salunke, Abhijeet Ashok; Chawla, Jasneet; Sharma, Aman; Sharma, Satyavan; Thivari, Praveen; Ratna, Harish V K

doi:10.1016/j.dsx.2020.09.027

Cited by 31 publications

(26 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is an extensive literature that supports the safety of ivermectin to treat a variety of parasitic infections as well as in vitro and in vivo data reflecting anti-SARS-CoV-2 effects (220). Although not receiving FDA approval for COVID-19 disease, ivermectin has been used for the treatment of the disease in a number of countries and notably in Peru where its use has been linked to a decrease in both mortality and lethality although in the absence of data from appropriate RCTs other non-drug related factors may have contributed to the apparent benefits of treatment (221,222). An exploratory Phase 1 clinical trial has been approved in the U.K. by the Medicines & Healthcare products Regulatory Agency) to determine the therapeutic efficacy of ivermectin as a low cost prophylactic to prevent the spread of COVID-19 (223).…”

Section: Ivermectin 3clpro and Plpro Inhibitorsmentioning

confidence: 99%

A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic

et al. 2021

View full text Add to dashboard Cite

COVID-19 emerged from China in December 2019 and during 2020 spread to every continent including Antarctica. The coronavirus, SARS-CoV-2, has been identified as the causative pathogen, and its spread has stretched the capacities of healthcare systems and negatively affected the global economy. This review provides an update on the virus, including the genome, the risks associated with the emergence of variants, mode of transmission, immune response, COVID-19 in children and the elderly, and advances made to contain, prevent and manage the disease. Although our knowledge of the mechanics of virus transmission and the immune response has been substantially demystified, concerns over reinfection, susceptibility of the elderly and whether asymptomatic children promote transmission remain unanswered. There are also uncertainties about the pathophysiology of COVID-19 and why there are variations in clinical presentations and why some patients suffer from long lasting symptoms—“the long haulers.” To date, there are no significantly effective curative drugs for COVID-19, especially after failure of hydroxychloroquine trials to produce positive results. The RNA polymerase inhibitor, remdesivir, facilitates recovery of severely infected cases but, unlike the anti-inflammatory drug, dexamethasone, does not reduce mortality. However, vaccine development witnessed substantial progress with several being approved in countries around the globe.

show abstract

Section: Ivermectin 3clpro and Plpro Inhibitorsmentioning

confidence: 99%

A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The scientific and medical community have been quick to adapt and have explored a plethora of therapeutic approaches. Treatments originally known for their efficacy against prior viral infections such as corticosteroids, and convalescent plasma (CP) have been repurposed for SARS-CoV-2 [22][23][24]. Recent novel treatments and vaccines have emerged such as the monoclonal antibodies casirivimab and imdevimab (REGN-COV2) and the Pfizer and Moderna mRNA vaccines [4].…”

Section: Current Treatments and Therapeutic Statusmentioning

confidence: 99%

Mesenchymal Stem Cells and Extracellular Vesicles: An Emerging Alternative to Combat COVID-19

Rodriguez¹,

Gupta²,

Cavazos-Escobar³

et al. 2022

Biotechnology to Combat COVID-19

View full text Add to dashboard Cite

The global SARS-CoV-2 outbreak has been accompanied with severe socio-economic and health burdens that will ripple through history. It is now known that SARS-CoV-2 induces a cytokine storm that leads to acute respiratory distress syndrome and systemic organ damage. With no definitive nor safe therapy for COVID-19 as well as the rise of viral variants the need for an urgent treatment modality is paramount. Mesenchymal stem cells (MSCs) and their extracellular vesicles (EVs) have long been praised for their anti-viral, anti-inflammatory and tissue regenerative capabilities. MSCs and their EVs are now being studied for their possible use as a treatment modality for COVID-19. In this review we explore their capabilities and outline the evidence of their use in ALI, ARDS and COVID-19.

show abstract

“…Finally, another drug—Ivermectin, an approved anti-parasitic drug—showed to be a promising candidate in early treatment of COVID-19 patients. The data was presented by the FLCCC Alliance [ 76 ] and is based on published studies showing its potential on SARS-CoV-2 inhibition [ 77 ].…”

Section: Strategies For Management Of Covid-19: Current Status Pitfalls and Obstaclesmentioning

confidence: 99%

A Perspective on COVID-19 Management

Pavelić

Brix

et al. 2021

JCM

View full text Add to dashboard Cite

A novel coronavirus—Severe Acute Respiratory Syndrome-Coronavirus 2 (SARS-CoV-2)—outbreak correlated with the global coronavirus disease 2019 (COVID-19) pandemic was declared by the WHO in March 2020, resulting in numerous counted cases attributed to SARS-CoV-2 worldwide. Herein, we discuss current knowledge on the available therapy options for patients diagnosed with COVID-19. Based on available scientific data, we present an overview of solutions in COVID-19 management by use of drugs, vaccines and antibodies. Many questions with non-conclusive answers on the measures for the management of the COVID-19 pandemic and its impact on health still exist—i.e., the actual infection percentage of the population, updated precise mortality data, variability in response to infection by the population, the nature of immunity and its duration, vaccine development issues, a fear that science might end up with excessive promises in response to COVID-19—and were raised among scientists. Indeed, science may or may not deliver results in real time. In the presented paper we discuss some consequences of disease, its detection and serological tests, some solutions to disease prevention and management, pitfalls and obstacles, including vaccination. The presented ideas and data herein are meant to contribute to the ongoing debate on COVID-19 without pre-selection of available information.

show abstract

Ivermectin in COVID-19: What do we know?

Cited by 31 publications

References 8 publications

A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic

A Comprehensive Review of Viral Characteristics, Transmission, Pathophysiology, Immune Response, and Management of SARS-CoV-2 and COVID-19 as a Basis for Controlling the Pandemic

Mesenchymal Stem Cells and Extracellular Vesicles: An Emerging Alternative to Combat COVID-19

A Perspective on COVID-19 Management

Contact Info

Product

Resources

About